Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
Mené sur 28 patients atteints d'un cancer du poumon non à petites cellules de stade localement avancé et non résécable (durée médiane de suivi : 18,2 mois ; âge médian : 70 ans ; 57 % d'hommes), cet essai évalue la dose maximale tolérée d'une radiothérapie stéréotaxique hypofractionnée, avec boost et associée à une chimiothérapie par carboplatine/paclitaxel
Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is associated with improved local control and overall survival compared with conventionally fractionated, nonablative regimens in early-stage non–small cell lung cancer (NSCLC). With modern imaging and treatment-delivery technology, the biologically effective doses (BED10, based on the linear-quadratic model assuming α/β = 10) of radiation delivered to small volumes of tumors can be substantially increased by using SBRT with higher doses per fraction in fewer numbers of fractions. A BED10 of 100 (including a regimen of 50 Gy in 5 fractions) is often considered a threshold above which SBRT can be considered ablative and definitive.
JAMA Oncology 2024